Tafamidis CAS:
CAS NO.Product Name TafamidisSynonymsFx-1006A; Vyndaqel; Fx1006A; Fx 1006AFormulaC14H7Cl2NO3Molecular Weight308.12Spec / Purity98%minSupply Capacity Details Tafamidis, also known as Fx-1006 or Fx-1006A, is a drug for the
amelioration of transthyretin-related hereditary amyloidosis (also familial
amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease.
The drug was approved by the European Medicines Agency in November 2011 and by
the Japanese Pharmaceuticals and Medical Devices Agency in September 2013.
Tafamidis functions by kinetic stabilization of the correctly folded tetrameric
form of the transthyretin (TTR) protein. In patients with FAP, this protein
dissociates in a process that is rate limiting for aggregation including amyloid
fibril formation, causing failure of the autonomic nervous system and/or the
peripheral nervous system (neurodegeneration) initially and later failure of the
heart.
Other supplier products
|
|
(-)-Huperzine A CAS: |
If you are going to consult the information about from one of the leading manufacturers and suppliers in China, Biopharmaleader Co.,Ltd is always... |
|
|
LY-3039478 CAS: |
If you are going to consult the information about from one of the leading manufacturers and suppliers in China, Biopharmaleader Co.,Ltd is always... |
|
|
|
,API |
|
|
|
,API |
|
|
|
If you are going to consult the information about from one of the leading manufacturers and suppliers in China,Website:, Biopharmaleader Co.,Ltd ... |
All supplier products
Same products
